Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug;40(8):759-762.
doi: 10.1016/j.healun.2021.04.003. Epub 2021 Apr 21.

BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response

Yael Peled  1 , Eilon Ram  2 , Jacob Lavee  2 , Leonid Sternik  2 , Amit Segev  2 , Anat Wieder-Finesod  3 , Michal Mandelboim  4 , Victoria Indenbaum  5 , Itzchak Levy  3 , Ehud Raanani  2 , Yaniv Lustig  4 , Galia Rahav  3
Affiliations

BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response

Yael Peled et al. J Heart Lung Transplant. 2021 Aug.

Abstract

Background: Data on the safety and efficacy of SARS-CoV-2 vaccines in immunocompromised populations are sparse.

Methods: We conducted a prospective study of 77 heart transplant (HT) recipients vaccinated with two doses of BNT162b2 vaccine and monitored for adverse events following both doses, the receptor-binding domain (RBD) IgG response, and neutralizing antibodies.

Results: BNT162b2 vaccination was associated with a low rate of adverse events, characterized mostly by pain at the injection site. By a mean 41 days post second dose there were no clinical episodes of rejection, as suggested by a troponin leak or allograft dysfunction. At a mean 21 days following the second dose, IgG anti-RBD antibodies were detectable in 14 (18%) HT recipients. Immune sera neutralized SARS-CoV-2 pseudo-virus in 8 (57%) of those with IgG anti-RBD antibodies. Immunosuppressive regimen containing mycophenolic acid was associated with lower odds of an antibody response (OR = 0.12, p = 0.042).

Conclusions: Whether a longer time-frame for observation of an antibody response is required after vaccination in immunosuppressed individuals remains unknown.

Keywords: BNT162b2 vaccine; antibody response; heart transplantation.

PubMed Disclaimer

Comment in

References

    1. Polack FP, Thomas SJ, Kitchin N. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–2615. - PMC - PubMed
    1. Voysey M, Clemens SAC, Madhi SA. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. - PMC - PubMed
    1. Boyarsky BJ, Werbel WA, Avery RK. Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients. JAMA. 2021;325:1784–1786. - PMC - PubMed
    1. Boyarsky BJ, Ou MT, Greenberg RS. Safety of the first dose of SARS-CoV-2 vaccination in solid organ transplant recipients. Transplantation. 2021;105:e56–e57. - PMC - PubMed
    1. International Society for Heart and Lung Transplantation Guidance from the International Society of Heart and Lung Transplantation regarding the SARS CoV-2 pandemic. Available at: https://ishlt.org/ishlt/media/Documents/COVID19_Vaccine-Recommendations_...